April 14, 2021 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Bio-Techne Announces Licensing of Proprietary Antibody to Xencor for Therapeutic Development

MINNEAPOLIS, April 14, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced a license agreement for use of a proprietary Bio-Techne antibody by Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, for its therapeutic development pipeline. Bio-Techne is a global life sciences company providing... Read more

April 12, 2021 Clinical Research/Diagn. M&A, Partnerships

Abcam and MEDx extend precision medicine strategic partnership

Cambridge, UK and Shanghai, China, 12 April : Today Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDxTranslational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key... Read more

April 11, 2021 Clinical Research/Diagn. Liq. Handling & Robotics M&A, Partnerships

Diasorin To Acquire Luminex Corporation for USD 37.00 per Share or Approximately USD 1.8 Billion

– Provides Access To Proven Luminex Multiplexing Technology And Molecular Testing Solutions To Be Used In Unique Testing Panels, Generating Critical Mass In The Molecular Diagnostics Space – Sets The Ground For New Partnerships And Business Development Opportunities Through Life Science Offerings – Broadens DiaSorin’s Presence In The U.S. – Accelerates Luminex Technology And Solutions’... Read more

April 6, 2021 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne Completes Acquisition of Asuragen, Inc.

MINNEAPOLIS, April 6, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc.  The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.  The Asuragen acquisition adds a leading portfolio of best-in-class molecular... Read more

March 25, 2021 Acad, Gov/Utilities Clinical Research/Diagn. Lab Top-10 Life Science Tools Liq. Handling & Robotics Microscopy Product Launch

Thermo Fisher Scientific Completes FDA Listing and Launches the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System for In Vitro Diagnostic Use

Thermo Fisher Scientific Completes FDA Listing and Launches the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System for In Vitro Diagnostic Use Innovative qPCR platform simplifies molecular diagnostic workflows for infectious disease, oncology and COVID-19 testing CARLSBAD, Calif., March 25, 2021 /PRNewswire/ — Thermo Fisher Scientific today announced the completion of the U.S. Food and Drug... Read more

March 23, 2021 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics M&A, Partnerships

Thermo Fisher Scientific Collaborates with Artificial to Enhance COVID-19 Diagnostic Testing Solution

Thermo Fisher Scientific Collaborates with Artificial to Enhance COVID-19 Diagnostic Testing Solution Collaboration agreement between Thermo Fisher Scientific and Artificial enables improved integration of software and robotics platforms to maximize COVID-19 testing throughput and efficiency TORONTO, March 23, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, and Artificial, developers of flexible automation... Read more

March 23, 2021 Bio/Pharma/CRO Clinical Research/Diagn. PAI Top-10 Product Launch

New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19

Investigational antibody cocktail of casirivimab and imdevimab also significantly shortened the duration of symptoms by four days The 2,400 mg and 1,200 mg doses tested in the phase III study had similar efficacy across all endpoints Companion dose-ranging phase II trial showed significant and comparable viral reductions for a range of doses of casirivimab and... Read more

March 16, 2021 Clinical Research/Diagn. Informatics & Software Lab Top-10 Product Launch

EUROIMMUN Launches Novel Ultrafast Automated Microscope and Intelligent Software for State-of-the-Art Diagnostics

WALTHAM, Mass. – March 16, 2021 – EUROIMMUN, a PerkinElmer, Inc. company, today announced the launch of the EUROPatternTM Microscope Live (EPML) compact immunofluorescence microscope, available with the fourth generation of the Company’s well-established EUROLabOfficeTM 4.0 (ELO 4.0) laboratory management software. The combined system of hardware and software allows for ultrafast automated immunofluorescence image acquisition,... Read more

March 15, 2021 Clinical Research/Diagn. Liq. Handling & Robotics M&A, Partnerships

Roche signs definitive merger agreement with GenMark Diagnostics, Inc., to access novel technology to test for broad range of pathogens with one patient sample

Basel, 15 March 2021 Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021 GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sample GenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the... Read more